AAVXF:OTCMKTS
Abivax SA
139,00 US$
0,00%
(0,00) 1K
9-iyl, 9:30:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoAAVXF tikeri uchun statistika yaratilmoqda...
Bozor kapitali
6,63 mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
139,00 US$
52 haftalik eng past
71,26 US$
Beta
3,09
Muomaladagi aksiyalar
87,53 mln
Xodimlar soni
98
Bozor kapitali
6,63 mlrd
Oʻrtacha hajm
0,00
Hajmi
0,00
52 haftalik eng yuqori
139,00 US$
52 haftalik eng past
71,26 US$
Beta
3,09
Muomaladagi aksiyalar
87,53 mln
Xodimlar soni
98
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
https://www.dars.gov.et/
·
5 kun oldin
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni98
Asos solingan4-dek, 2013
Bosh ofislar-
Sektor-
Veb-saytabivax.com